A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC).
- Who it may be relevant to
- Registry conditions: High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma. Basic parameters: 0 years — 39 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) and Cemiplimab Alone Followed by Adjuvant Fianlimab in Combination With Cemiplimab in Pediatric and Young Adult Participants With Recurrent or Progressive High-Grade Glioma or Pediatric and Adult Participants With Recurrent or Progressive Posterior Fossa-A Ependymoma
Overview
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs"). The study is focused on children and young adults with recurrent or progressive High-Grade Glioma (HGG) or ependymoma. "Recurrent" means that the cancer came back after treatment. "Progressive" means that the tumor has grown or spread. The aim of the study is to see how safe, tolerable, and effective cemiplimab and the combination of fianlimab and cemiplimab are. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug(s) * Do the study drug(s) help study participants live longer without their tumors growing or spreading * How much of the study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug\[s\] less effective or lead to side effects)
Interventions
- Drug Cemiplimab
Administered per the protocol - Drug Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
Administered per the protocol
Primary outcome measures
- Occurrence of Treatment Emergent Adverse Events (TEAEs) [Time frame: Up to 26 months]
- Severity of TEAEs [Time frame: Up to 26 months]
- Overall Survival (OS) [Time frame: 12 months]
- Progression Free Survival (PFS) [Time frame: 12 months]
Secondary outcome measures (11)
- Concentrations of fianlimab in serum [Time frame: Up to 5 years]
- Concentrations of cemiplimab in serum [Time frame: Up to 5 years]
- Occurrence of Anti-Drug Antibody (ADA) to fianlimab [Time frame: Up to 5 years]
- Occurrence of ADA to cemiplimab [Time frame: Up to 5 years]
- Magnitude of ADA to fianlimab [Time frame: Up to 5 years]
- Magnitude of ADA to cemiplimab [Time frame: Up to 5 years]
- Progression Free Survival (PFS) [Time frame: Up to 5 years]
- Death due to any cause [Time frame: Up to 5 years]
- Overall Survival [Time frame: Up to 5 years]
- Occurrence of TEAEs [Time frame: Up to 5 years]
- Severity of TEAEs [Time frame: Up to 5 years]
Eligibility criteria
Inclusion criteria
- Participant must be diagnosed with recurrent/progressive HGG or PF-A ependymoma with unequivocal progression on Magnetic Resonance Imaging (MRI) as described in the protocol
- Participant must have histologically confirmed (at initial diagnosis or relapse) HGG or PF-A ependymoma
- Participant must be an adequate medical candidate for surgical resection as described in the protocol
- Karnofsky Performance Status (KPS) score ≥50 (in participants ≥16 years) or Lansky Performance Status (LPS) score ≥50 (in participants <16 years) as described in the protocol
- Adequate organ function as described in the protocol
Exclusion criteria
- Active autoimmune disease requiring systemic immunosuppressive therapy in the past 2 years
- Active, serious medical illness, infection or other systemic illness which would limit participation in the trial
- Has not yet recovered from any acute toxicities resulting from prior therapy
- History of myocarditis
- Prior treatment with antibodies to Programmed Cell Death Protein -1 (PD-1), Programmed Cell Death Protein Ligand -1 (PD-L1), Lymphocyte Activation Gene 3 (LAG3), or Cytotoxic T-Lymphocyte Associated protein 4 (CTLA-4)
- Treatment with high dose systemic corticosteroids as described in the protocol
- History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management
Note: Other protocol defined Inclusion/ Exclusion Criteria apply
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07567469 · R3767-ONC-2320 · 2025-521485-96-00